Avelumab and Merkel Cell Carcinoma: Examining Biological Plausibility
From General Health Surveillance to Occupational Exposure Inquiry
The legacy of general health and science information has long emphasized population-level data collection, continuous surveillance, and the evaluation of outcomes against standard definitions. This heritage, drawn from public health monitoring and epidemiological frameworks, provides a foundation for understanding how environmental and behavioral factors influence disease patterns. Within this broad context, the transition from general health concerns to specific occupational exposure considerations becomes a natural progression. As mass production environments introduce distinct chemical and biological agents, the principles of systematic data gathering and outcome assessment are directly applicable. The shift in focus moves from broad lifestyle and dietary factors, such as those observed in population weight studies, toward the scrutiny of workplace-related exposures. This pivot acknowledges that occupational settings can present unique risk profiles that warrant targeted investigation. The same rigorous methodologies used to track community health trends can be adapted to examine potential links between industrial exposures and adverse health outcomes. Thus, the established public health surveillance framework serves as a bridge, enabling a focused inquiry into whether specific occupational exposures, such as those encountered in pharmaceutical manufacturing or clinical administration, may correlate with increased disease risk, without yet specifying any particular mechanism or causal pathway.
Bridging to Avelumab and Merkel Cell Carcinoma
Building on the general surveillance framework, we now turn to a specific therapeutic agent: avelumab, a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/;https://pubmed.ncbi.nlm.nih.gov/33439294/). The approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). While avelumab is indicated for MCC, the question of whether avelumab can cause or contribute to the development of MCC requires an examination of biological plausibility, mechanistic pathways, and clinical evidence.
Mechanistic Pathways and Etiological Considerations
MCC has two primary etiologies: approximately 80% of cases are caused by the human Merkel cell polyomavirus (MCPyV), while the remaining 20% are induced by ultraviolet (UV) light, leading to a high mutational burden (https://pubmed.ncbi.nlm.nih.gov/34445385/). Avelumab, as an anti-PD-L1 inhibitor, works by blocking the PD-1/PD-L1 interaction, thereby enhancing T-cell responses against tumor cells (https://pubmed.ncbi.nlm.nih.gov/29799096/). In the context of MCC, avelumab is used to treat existing disease, not to induce it. However, immune checkpoint inhibitors, including avelumab, are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). These irAEs can include conditions such as sarcoidosis, as reported in a case of hypercalcaemia secondary to reactivation of sarcoidosis during avelumab treatment for metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/31543781/). The biological plausibility of avelumab causing MCC is not supported by the known mechanism of action, as avelumab enhances immune surveillance rather than promoting oncogenesis. In fact, response rates to PD-1/PD-L1 inhibition in metastatic MCC can reach up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/), indicating that avelumab is generally beneficial in this patient population.
Clinical Evidence and Risk Context
Nevertheless, approximately 50% of patients do not respond to immune checkpoint inhibitors or develop irAEs due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). For avelumab-refractory patients, efficient and safe treatment options are lacking, though combined ipilimumab and nivolumab has shown activity in some cases (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/36450381/). The timeline between avelumab exposure and documented harm, such as irAEs, can vary. In the reported case of sarcoidosis reactivation, hypercalcaemia was managed with corticosteroids, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This suggests that while avelumab can trigger immune-related adverse events, these are typically manageable and do not involve the development of new malignancies like MCC. Regarding causation-related considerations for affected patients, the adequacy of warnings about avelumab and MCC is critical. The prescribing information for avelumab includes warnings about immune-mediated adverse reactions, but the specific risk of developing MCC as a direct consequence of avelumab treatment is not established in the literature. The evidence indicates that avelumab is used to treat MCC, and no studies have demonstrated that avelumab causes MCC. In fact, the JAVELIN Merkel 200 trial showed that avelumab leads to tumor regression in a subset of patients with pre-existing MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). The risk anchors for affected patients should focus on the known irAEs, such as sarcoidosis, rather than on MCC causation, as the latter lacks biological plausibility and clinical evidence.
Summary of Biological Plausibility
In summary, the biological plausibility of avelumab causing Merkel cell carcinoma is not supported by the available evidence. Avelumab is an effective treatment for MCC, and its mechanism of action involves immune activation against tumor cells, not oncogenesis. While immune-related adverse events are documented, they do not include the development of new MCC cases. The timeline between avelumab exposure and harm is typically associated with irAEs, which are manageable and do not involve MCC induction. Warnings regarding avelumab should emphasize immune-mediated adverse events rather than MCC causation, as the latter is not substantiated by current data.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
Can avelumab cause Merkel cell carcinoma?
No, the available evidence does not support that avelumab causes Merkel cell carcinoma. Avelumab is an immune checkpoint inhibitor used to treat MCC, and its mechanism of action enhances immune surveillance against tumor cells, not oncogenesis. Clinical trials have shown tumor regression in patients with pre-existing MCC, and no studies have demonstrated that avelumab induces new MCC cases.
What are the known risks of avelumab treatment?
Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system, such as sarcoidosis, as reported in a case of hypercalcaemia secondary to reactivation of sarcoidosis during avelumab treatment for metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/31543781/). These irAEs are typically manageable with corticosteroids and do not involve the development of new malignancies like MCC.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.